Kabanat (cabazitaxel) Injection is used for the treatment of patients with hormone-refractory metastatic prostate cancer.

Kabanat is a microtubule inhibitor indicated in combination with prednisone for treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing treatment regimen.

Kabanat (cabazitaxel) Injection suppliers in India. Indian Pharma Network (IPN) New Delhi, INDIA.

IPN is a facilitator under Patient Assistance Programs. Expertise in Specialty Pharmaceutical distribution having its PAN India presence in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow, north East and Pune and other cities in India. with over 20 years of domain experience.

For procurement cost of Kabanat (cabazitaxel) Injection brand in India, sold by indian drug manufacturer. Please call at M: +91 9811747774 (Mr. Tarun) / 9891296838 (Mr. Neeraj) or Email Us to know more details about the Kabanat (cabazitaxel) Injection cost price in India.

The order for Kabanat (cabazitaxel) Injection will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.

Cabazitaxel (previously XRP-6258, trade name Jevtana) is a semi-synthetic derivative of a natural taxoid. It was developed by Sanofi-Aventis and was approved by the U.S. FDA for the treatment of hormone-refractory prostate cancer on June 17, 2010. It is a microtubule inhibitor, and the fourth taxane to be approved as a cancer therapy.

Kabanat (cabazitaxel) Injection, 60 mg/1.5 mL, for intravenous infusion only

Generic Name: cabazitaxel

Single use vial 60 mg/1.5 mL, supplied with diluent (5.7 mL)

Kabanat (cabazitaxel)

GET IN TOUCH
with Indian Pharma Network

Indian Pharma Network, Delhi provides access to KABANAT (cabazitaxel) on the Named Patient Import basis in India.

Indian Pharma Network (IPN), Delhi. India

IPN, Delhi is registered organisation in India, having highly qualified healthcare professionals of pharmaceutical Industry. Specialized in Oncology Products. Helped more than 6,000 patients. Registration Number : 07AAFFI2544E1ZO under GST Act. On the basis of permission in Form 12B (Import permit) from From Ministry of Health, Government of India. IPN, New Delhi helps patient, providing solutions on how to get access of anti cancer medicines which is not available in India.

BRANCH OFFICE : NEW DELHI | BENGALURU | KOLKATA | LUCKNOW | JODHPUR

Our Overseas Network UK | Russia | Brazil | Mexico | Germany | France| Italy | Spain | Japan | China| Australia | Saudi Arabia | South Africa

Indian Pharma Network

60/4 1st Floor, T&T Building, Indian Oil Complex,
Yusuf Sarai, New Delhi, Delhi 110016

Mobile / WhatsApp / Phone

M: +91 9811747774, 9891296838.
P: +91-11-26532129 / 26536398

Free Customer Support

info@indianpharmanetwork.co.in
urgent@indianpharmanetwork.co.in

Kabanat (cabazitaxel) Injection suppliers in India

IPN helps patients, doctors and hospitals as a facilitator to import prescription medicine brand Kabanat (cabazitaxel) Injection on prescription and Import License in Patient's Name only.

For overseas patients, Kabanat (cabazitaxel) Injection can be made available in Send your enquiry to find Kabanat (cabazitaxel) Injection in China, Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong. UAE Iraq, Iran, Saudi Arabia, Jordan, Mexico, Argentina, Brazil, Chile, Colombia, Peru, Venezuela. Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia. Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia, Algeria, Mauritius, Uganda, Zimbabwe. Australia and New Zealand.

News / Update for Kabanat (cabazitaxel) Injection.

For Kabanat (cabazitaxel) Injection Indications And Usage, Dosage And Administration, Dosage Forms And Strengths and Drug Interactions For More Details

Cabazitaxel vs abiraterone or enzalutamide in metastatic prostate cancer For More Details

Addition of Carboplatin to Cabazitaxel Promising for mCRPC